B cell maturation antigen (BCMA), type III transmembrane receptor which belongs to tumor necrosis factor superfamily member 17, known as TNFRSF17/CD269, is one of the most attractive antigens in the development of immunotherapies of MM, because it is exclusively expressed in most plasma cells, compared with CD38 and SLAMF7. Here, CD38 is linked to Miyoshi myopathy.